Comparative Pharmacology
Head-to-head clinical analysis: CYRAMZA versus VEGZELMA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYRAMZA versus VEGZELMA.
CYRAMZA vs VEGZELMA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ramucirumab is a human IgG1 monoclonal antibody that binds to vascular endothelial growth factor receptor 2 (VEGFR-2) and blocks the interaction between VEGFR-2 and its ligands, VEGF-A, VEGF-C, and VEGF-D, thereby inhibiting receptor activation and subsequent angiogenesis.
VEGZELMA (bevacizumab-awwb) is a humanized monoclonal antibody that binds to vascular endothelial growth factor (VEGF) and inhibits VEGF receptor binding, thereby reducing angiogenesis and tumor vascularization.
8 mg/kg intravenously every 2 weeks or 10 mg/kg intravenously every 2 weeks if used in combination with paclitaxel or FOLFIRI.
Intravenous infusion, 240 mg every 2 weeks or 480 mg every 4 weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 14 days (range 11–17 days) at steady state, supporting a dosing interval of every 2 weeks.
Terminal half-life: 11-14 hours (supports twice-daily dosing; no significant accumulation with normal renal function)
Ramucirumab is eliminated primarily via proteolytic catabolism; no renal or biliary excretion occurs. Clearance is 0.014 L/h (0.022 L/h with high VEGF), with a mean terminal half-life of 14 days (range 11–17 days) at steady state.
Renal: 70% (metabolites); Fecal: 30% (unchanged drug and metabolites)
Category C
Category C
Antineoplastic Monoclonal Antibody
Antineoplastic Monoclonal Antibody